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Abstract
Background: Bipolar disorder is a serious and common psychiatric disorder characterized by manic and depressive
mood switches and a relapsing and remitting course. The cornerstone of clinical management is stabilization and
prophylaxis using mood-stabilizing medications to reduce both manic and depressive symptoms. Lithium remains
the gold standard of treatment with the strongest data for both efficacy and suicide prevention. However, many
patients do not respond to this medication, and clinically there is a great need for tools to aid the clinician in
selecting the correct treatment. Large genome wide association studies (GWAS) investigating retrospectively the
effect of lithium response are in the pipeline; however, few large prospective studies on genetic predictors to of
lithium response have yet been conducted. The purpose of this project is to identify genes that are associated with
lithium response in a large prospective cohort of bipolar patients and to better understand the mechanism of
action of lithium and the variation in the genome that influences clinical response.
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Methods/Design: This study is an 11-site prospective non-randomized open trial of lithium designed to ascertain a
cohort of 700 subjects with bipolar I disorder who experience protocol-defined relapse prevention as a result of
treatment with lithium monotherapy. All patients will be diagnosed using the Diagnostic Interview for Genetic
Studies (DIGS) and will then enter a 2-year follow-up period on lithium monotherapy if and when they exhibit a
score of 1 (normal, not ill), 2 (minimally ill) or 3 (mildly ill) on the Clinical Global Impressions of Severity Scale for
Bipolar Disorder (CGI-S-BP Overall Bipolar Illness) for 4 of the 5 preceding weeks. Lithium will be titrated as clinically
appropriate, not to exceed serum levels of 1.2 mEq/L. The sample will be evaluated longitudinally using a wide
range of clinical scales, cognitive assessments and laboratory tests. On relapse, patients will be discontinued or
crossed-over to treatment with valproic acid (VPA) or treatment as usual (TAU). Relapse is defined as a DSM-IV
manic, major depressive or mixed episode or if the treating physician decides a change in medication is clinically
necessary. The sample will be genotyped for GWAS. The outcome for lithium response will be analyzed as a time to
event, where the event is defined as clinical relapse, using a Cox Proportional Hazards model. Positive single
nucleotide polymorphisms (SNPs) from past genetic retrospective studies of lithium response, the Consortium on
Lithium Genetics (ConLiGen), will be tested in this prospective study sample; a meta-analysis of these samples will
then be performed. Finally, neurons will be derived from pluripotent stem cells from lithium responders and non-
responders and tested in vivo for response to lithium by gene expression studies. SNPs in genes identified in these
cellular studies will also be tested for association to response.
Discussion: Lithium is an extraordinarily important therapeutic drug in the clinical management of patients
suffering from bipolar disorder. However, a significant proportion of patients, 30–40 %, fail to respond, and there is
currently no method to identify the good lithium responders before initiation of treatment. Converging evidence
suggests that genetic factors play a strong role in the variation of response to lithium, but only a few genes have
been tested and the samples have largely been retrospective or quite small. The current study will collect an
entirely unique sample of 700 patients with bipolar disorder to be stabilized on lithium monotherapy and followed
for up to 2 years. This study will produce useful information to improve the understanding of the mechanism of
action of lithium and will add to the development of a method to predict individual response to lithium, thereby
accelerating recovery and reducing suffering and cost.
Trial registration: ClinicalTrials.gov
Identifier: NCT01272531
Registered: January 6, 2011
Keywords: Bipolar disorder, Lithium, Mood stabilizer, Pharmacogenetics, GWAS, Prospective trial, Personalized
medicine, Precision medicine
Background
Clinical presentation and treatment of bipolar disorder
Bipolar disorder is a major psychiatric disorder described
by alternations between the extreme mood states of mania
and depression and characterized by episodic relapses and
chronic disability [1]. Bipolar disorder affects approxi-
mately 1 % of the population worldwide. It is a major
cause of hospitalizations and healthcare expenditures, as
well as suicide [2].
While there is no cure for bipolar disorder, it is a highly
treatable and manageable illness. After an accurate diag-
nosis, most people (80–90 %) can achieve substantial
stabilization of their mood and related symptoms with
proper treatment. Medications known as mood stabilizers
are usually prescribed to help control bipolar disorder.
These are used both in the acute treatment of episodes
and as maintenance treatment to prevent new episodes.
The medications are in general effective in both the manic
and depressive phases of the illness, hence the term mood
stabilizer. However, in practice, these medications tend to
be more effective against acute mania than acute
depression.
The action of lithium as a mood stabilizer was first iden-
tified by John Cade [3]. Since that time, it has remained
the standard against which other medications are com-
pared [4]. Several different types of mood stabilizers are
available in addition to lithium. These include some, but
not all, anticonvulsants such as valproate, carbamazepine,
and lamotrigine [5]. Atypical antipsychotics such as olan-
zapine, risperidone, aripiprizole and quetiapine also have
demonstrated efficacy as mood stabilizers [5].
Though there are now many effective mood stabilizers,
lithium has remained the treatment of choice for bipolar
disorder. Although lithium is effective in the majority of
patients, 30–40 % fail to respond. Furthermore, a sub-
stantial number of patients cannot be maintained on
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lithium because of intolerable side effects such as weight
gain, acne, thyroid suppression, and renal impairment.
In recent years, clinical data have demonstrated that
valproic acid, lamotrigine, olanzapine and other medica-
tions may have comparable efficacy to lithium [6–8].
Furthermore, these novel mood stabilizers have been
thought to have a more benign side effect profile and to
be better tolerated by patients. For these reasons, valproic
acid, lamotrigine, olanzapine, aripiprizole, and quetiapine
have begun to supplant lithium as the most frequently
prescribed medication for bipolar disorder. However, the
cost of treatment with these newer agents is in excess of
10 times higher than that of lithium ($60/mo for valproic
acid vs. $15/mo for olanzapine vs. $1/mo for lithium).
Also, other recent clinical studies, such as the BALANCE
trial, have demonstrated superior overall efficacy of lithium
for relapse prevention in comparison to valproate [9, 10].
Furthermore, a subset of patients do extremely well on lith-
ium and have excellent control of episodes with few, if any,
side effects.
As detailed below, a variety of data argue that good lith-
ium responders constitute a clinically and genetically dis-
tinct group. As there is currently no method to identify
this subset of lithium responders, lithium is being used
less frequently despite the fact that many patients would
respond very well to it. Furthermore, many patients who
might have been excellent lithium responders are never
able to benefit from lithium treatment because lithium is
never tried. Development of a method to predict individ-
ual response to lithium before initiation of treatment
would, therefore, be of great benefit to clinicians in mak-
ing prescribing decisions and in accelerating recovery and
reducing cost.
Predictors of response
A variety of clinical and biological predictors, as well as
genetic data, suggest that lithium-responsive bipolar dis-
order may comprise a mechanistically distinct form of
illness.
Clinical predictors
A recent scholarly review of the various predictors of good
and poor outcome following long-term treatment with lith-
ium proposes a useful nomenclature that classifies these
predictors according to category [11]. Psychopathological
predictors of good response include initial good response
within 6–12 months (highly reliable), classic euphoric/
elated mania, positive family history of bipolar disorder
with a good response to lithium in particular, the absence
of a personality disorder, bipolar I disorder (as opposed to
type II), the mania-depression-euthymic pattern of illness
course, the presence of melancholic features during depres-
sive episodes, and early onset of lithium therapy. Predictors
of poor response in this category included mixed episodes
(highly reliable), rapid cycling, mood incongruent psychotic
symptoms, onset before the age of 18, high numbers of life-
time mood episodes, and the depression-mania-euthymia
pattern of illness course. The most highly replicated envir-
onmental predictor is that of being single, not married.
Biological predictors
Biological predictors of good response to lithium include
high RBC/plasma-lithium ratio (highly controversial),
higher platelet serotonin-induced calcium mobilization,
and high rate of red blood cell membrane phospholipids
in lithium intracellular transport. Neurophysiologic pre-
dictors of good response include brain lithium concentra-
tions above 0.2 mEq/L when measured by 7Li-MRS,
decreased cerebral intracellular pH, white matter hyperin-
tensity at (31)P-MRS, and high intensity of loudness
dependent auditory evoked potentials. Neurophysiologic
predictors of poor response have included epileptiform
anomalies with diffuse theta waves on EEG and decreased
cerebral phosphocreatinine levels at (31)P-MRS. Genetic
predictors of good response include lower inositol mono-
phosphatase mRNA expression and a high frequency of
phospholipase C isoenzyme gamma-1. Genetic predictors
of poor response include homozygotic forms of the short
allele of the serotonin transporter gene (5-HTT), the pres-
ence of the A/A subtype of tryptophan hydroxylase
(TPH), and a high frequency of human leukocyte antigens
type A3 (HLA-A3).
Mechanism of action of lithium
A major challenge in the discovery of genes for mood
stabilizer response is the lack of understanding of the
pathophysiology of the disease and the mechanism of
action of the existing medications. Lithium, as the oldest
mood stabilizer, has received the most attention in
terms of its mechanism of action. A variety of protein
targets and signal transduction processes have been re-
ported to be inhibited by lithium. Therefore, the chal-
lenge has been determining which of these mechanisms
are therapeutically important. Some of the earliest stud-
ies reported that cAMP generation in response to
adrenaline was inhibited by lithium [12]. Early on the
theme began to emerge that inhibition of both sides of
systems in balance led to an overall stabilization and re-
duced biochemical swings that might in turn underlie
behavioral swings. One of the first such observations
was that cAMP and cGMP production by norepineph-
rine and epinephrine, respectively, were both inhibited
by lithium [13]. Lithium was also later reported by the
same group to inhibit both adrenergic- and cholinergic-
induced GTP binding in rat brain [14]. G proteins as a
target of lithium received further support with the ob-
servation that lithium inhibits expression of the gene for
Gαi [15] and that it inhibits the action of Gαs [16].
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The inositol signaling pathway has also been a major
focus of lithium studies. In response to receptor stimula-
tion, phospholipase C (PLC) breaks down phosphotidyl in-
ositol 4,5-biphosphate (PIP2) to inositol 1,4,5-triphosphate
(IP3) and diacylglycerol (DAG). These products act as
intracellular signaling molecules triggering the release of
calcium from intracellular stores and activating protein
kinase C (PKC). Inositol monophosphatase (IMPase) and
inositol polyphosphatase (IPPase) then dephosphorylate
IP3 and IP2 and recycle free inositol to the membrane.
Lithium has been observed to inhibit IMP and IPP, leading
to the hypothesis that lithium treatment leads to a deple-
tion of free inositol, thereby inhibiting this signaling path-
way [17, 18].
Protein kinase C is a downstream target of phosphoinosi-
tide signaling that has received extensive attention. PKC ac-
tivity has been shown to be reduced by lithium [19] and
has been reported to be elevated in mania [20]. At doses
adequate to inhibit PKC, tamoxifen has been shown to have
anti-manic properties clinically [21]. Lithium also reduces
the levels of a major substrate of PKC, myristoylated
alanine-rich C kinase substrate (MARCKS) [22].
The profound effects of lithium on morphogenesis in
Drosophila led to a novel hypothesis of lithium’s mech-
anism of action [23]. Wnt signaling proteins bind to
transmembrane frizzled receptors and inhibit glycogen
synthase kinase 3β (GSK3β) via disheveled. This inhib-
ition in turn promotes the stabilization of β-catenin.
Lithium was shown to inhibit GSK3β and thereby mimic
the effect of wnt signaling [24]. Lastly, the most recent
and novel proposed mechanism of action of lithium in-
volves neuroprotection. Lithium has been shown to pro-
tect neuronal cultures from glutamate-induced apoptosis
[25]. Lithium has also been shown to increase expression
of the anti-apoptotic protein, bcl-2 [26]. The neuropro-
tective effect of lithium may also be mediated by stimu-
lating the phosphorylation of Akt-1 by phosphoinositide
kinase (PI3-K), which in turn phosphorylates GSK3β
[27]. This process may inhibit the pro-apoptotic action
of GSK3β.
Lithium-mediated gene expression
There are likely hundreds if not thousands of genes that are
modulated in some way by lithium. Data have been emer-
ging for the past several years that clearly demonstrate
lithium-mediated gene expression changes. Bosetti et al. re-
ported changes in the expression of a variety of genes in re-
sponse to lithium, including those from signal transduction
pathways [28]. The study of a larger gene array with 39,000
transcripts in mice [29] reported 4,474 genes with nomin-
ally significant expression changes and 121 with a stringent
Bonferroni correction. There were 13 genes affiliated with
phosphotidylinositol metabolism, again consistent with the
cell signaling pathway hypothesis. One of the more
comprehensive studies reported to date used a human
neuronal cell line (SK-N-AS), and they reported 347 up-
regulated and 324 downregulated genes, from 3 primary
pathways: the mitogen-activated protein kinase (MAPK)
signaling pathway, an actin cytoskeleton pathway and a
calcium signaling pathway [30].
Expression patterns of micro RNAs (miRNA) in the
hippocampus of rats have shown that lithium and val-
proate both decreased the expression of several miRNAs
considered candidates for bipolar disorder; including the
pathways involving Wnt/βcatenin [31]. A study of
miRNA in lymphoblastoid cell lines found increased ex-
pression when exposed to lithium, with a clear variation
in expression patterns with time, reflecting the dynamic
biological system wherein gene expression is unlikely to
be static [32].
Genetics of mood stabilizer response
There is much evidence to suggest that genetic factors
play a strong role in the variation in response to lithium.
Several studies have indicated that lithium-responsive
patients are more likely to have a stronger family history
of bipolar disorder than lithium non-responders [33, 34].
Mendlewicz et al. have reported better lithium prophy-
laxis in concordant bipolar twin pairs than in discordant
pairs [35]. Grof et al. have shown that affected relatives
of lithium-responsive bipolar probands are more likely
to also be lithium responsive than the relatives of non-
lithium-responsive probands [36]. Based on the idea that
lithium-responsive bipolar disorder is a distinct genetic
subtype, several studies have focused on this phenotype
for mapping genes for bipolar disorder. Turecki et al.
have reported a genome scan of such families with sig-
nificant evidence of linkage to a locus on 15q [37]. Two
studies have reported association of the gene PLCG1 to
lithium-responsive bipolar disorder [38, 39]. Two spe-
cific genes have been reported to be associated with re-
sponse to lithium in a comparison of responders and
non-responders: the serotonin transporter [40] and in-
ositol polyphophatase (INPP1) [41]. One GWAS has
been performed on a subset of the STEP-BD sample in-
cluding 359 bipolar I or bipolar II patients [42]. The
strongest region was on 10p15 (p = 10-7), and the gene
GRIA2 also showed some evidence for association.
Research objectives
Aim
The long-term goal of this project is to better under-
stand the mechanism of action of lithium and variation
in the genome that influences response. Practically, the
hope is that this understanding may lead to a DNA test
that would aid physicians in selecting mood stabilizers.
It also may add to our understanding of bipolar disorder
by distinguishing a genetically distinct form.
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Specific aims
1. A prospective trial of mood stabilizer response will be
conducted at a group of 11 closely collaborating sites.
a. The study will have an algorithmic design. All
patients will be started on lithium. Those that fail
lithium will be crossed over to valproic acid
(VPA). Those that fail VPA will be crossed over
to a standardized treatment as usual (TAU) arm.
b. The study will be designed to identify genes for
relapse prevention. All patients will be stabilized
on lithium monotherapy and then enter the
maintenance phase where they will be followed
for 2 years or until relapse. On relapse, they will
be discontinued or crossed over as appropriate.
c. The prospective sample will be genotyped for
GWAS. Positive SNPs from the Consortium on
Lithium Genetics (ConLiGen) will first be
selectively tested to control multiple comparisons.
Following this, a complete GWAS on the
prospective sample will be performed as well as a
meta-analysis with ConLiGen.
2. Mechanistic studies of lithium response will be
conducted as part of the project.
a. Skin biopsies will be collected on 100 patients
from the prospective study. Fibroblasts from 10
lithium responders and 10 non-responders will be
reprogrammed to induced pluripotent stem cells
(iPSCs).
b. iPSCs will be differentiated into neural progenitor
cells (NPCs) and then into mature neurons.
c. Pathways will be identified that are altered in
lithium responsive vs. non-responsive NPCs and
mature neurons. Cells will be treated with and
without lithium and RNA-seq will be conducted.
Genes whose expression is altered by lithium in
lithium responders and not non-responders will
be identified as possibly involved in lithium
response. SNPs in these genes will be tested
for association with response in the human
prospective data. Similarly, genes associated
with lithium response in the human studies
will be tested for change in the cell culture
models. Network and pathway analysis will be
applied to the expression data. Expression in
iPSC-derived neurons will be used to predict
networks of
related genes. These networks will be tested as
groups of genes in the human association
data.
d. Specific neuronal deficits will be sought in
patient neurons in vitro. Expression profiling
results will guide our exploration of cellular
phenotypes.
Methods and design
This study is an 11-site prospective, non-randomized
open trial of lithium designed to ascertain a cohort of
subjects with bipolar I disorder who experience
protocol-defined relapse prevention as a result of treat-
ment with lithium monotherapy. Prior to entry into the
1-month Observation Lithium Monotherapy Phase,
three routes of entry will be permitted.
1) Lithium Naïve Patients (LNP): LNPs will enter a
3-month Open Stabilization Phase designed to
prospectively demonstrate response to lithium either
as a component of Treatment As Usual (TAU) or
monotherapy before entry into the 1-month
Observation Lithium Monotherapy Phase. LNPs
will enter the 1-month Observation Lithium
Monotherapy Phase if and when they exhibit a
score of 1 (normal, not ill) or 2 (minimally ill) on
the Clinical Global Impressions of Severity Scale
for Bipolar Disorder (CGI-S-BP Overall Bipolar
Illness).
2) Currently Lithium-treated Patients (CLTP): CLTPs
on lithium monotherapy will enter the 1-month
Observation Lithium Monotherapy Phase when they
exhibit a score of 1, 2 or 3 on the CGI-S-BP Overall.
For CLTPs as a component of TAU, they will spend
up to 3 months during the Open Stabilization Phase
slowly weaning off all other psychotropic medications.
Once lithium monotherapy is achieved and a score of
1, 2 or 3 on the CBI-S-BP Overall is observed, they
will immediately enter the 1-month Observation
Lithium Monotherapy Phase.
3) Inadequate Past Lithium-treated Patients (IPLT):
IPLTs currently not taking lithium but believed to
have had an inadequate past trial of lithium, either
due to inadequate dose, blood level, duration, or
adherence to treatment, will enter the 3-month Open
Stabilization Phase to prospectively demonstrate
response to an adequate trial of lithium (either as a
component of TAU or monotherapy). IPLTs will enter
the 1-month Observation Lithium Monotherapy
Phase if and when they exhibit a score of 1 (normal,
not ill) or 2 (minimally ill) on the CGI-S-BP.
Three-month open stabilization phase and One-month
observation phase
Lithium, either as a component of guideline-driven adjunct-
ive treatment or monotherapy, will be permitted during the
Open Stabilization Phase as clinically indicated. Patients re-
ceiving combination therapy will be carefully transitioned
to lithium monotherapy as clinically appropriate. During
the 1-month Observation Lithium Monotherapy Phase, the
CGI-S-BP Overall will be used to describe stability (defined
as 4 out of 5 contiguous weeks of a score of 1 or 2), but the
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study will also assess other relevant outcomes, including
depression symptom severity (Montgomery Asberg
Depression Rating Scale-MADRS), mania symptom-
severity (Young Mania Rating Scale-YMRS), quality of
life (Quality of Life Enjoyment and Satisfaction Ques-
tionnaire-Q-LES-Q), suicidal behaviors, etc. Following the
successful completion of a 3-month Stabilization Phase (if
necessary) and a 1-month Observation Lithium Mono-
therapy Phase, patients meeting ‘a priori’ criteria for inclu-
sion in the Relapse Prevention Phase will be studied for
up to 24 months.
Participants
Inclusion Criteria: 1) Any phase of bipolar I disorder, in-
cluding depressive, manic, hypomanic, mixed, or base-
line/euthymic/not symptomatic; 2) LNPs and IPLTs(as
meant?) will be required to have had at least one
affective episode in the last 12 months meeting DSM-IV
criteria, but CLTPs will be exempted from this criterion
if they present without any history of mood episodes
meeting DSM-IV criteria in the last 6 months; 3) both
outpatients and inpatients will be permitted to enroll
into this study; 4) they must be able to give informed
consent, in the judgment of the investigator; 5) age
greater than or equal to 18 years; 6) women of child-
bearing potential agree to inform their doctor at the
earliest possible time of their plans to conceive, to use
adequate contraception (e.g. oral contraceptives, intra-
uterine device, barrier methods, or total abstinence
from intercourse), and to understand the risks of lith-
ium to the fetus and infant. Depo Provera is acceptable
if it is started 3 months prior to enrollment; 7) currently
symptomatic, as defined as a CGI-S-BP-Overall of
greater than or equal to 3 (mild severity), unless the pa-
tient enters the study already stable on lithium
monotherapy.
Exclusion Criteria: 1) Unwilling or unable to comply
with study requirements; 2) renal impairment (serum
creatinine >1.5 mg/dL); 3) thyroid stimulating hormone
(TSH) level over >20 % above the upper normal limit
(participants maintained on thyroid medication must be
euthyroid for at least 3 months before Visit 1; 4) other
contraindications to lithium, as will be defined in the
medication manual; 5) currently in crisis such that in-
patient hospitalization or other crisis management
should take priority; 6) although we have not excluded
all subjects meeting criteria for alcohol/drug depend-
ence, those meeting criteria for physical dependence re-
quiring acute detoxification from alcohol dependence,
opiate dependence or barbiturate dependence will be
excluded; 7) pregnant or breastfeeding; 8) women of
child-bearing potential who aren’t able to agree to the
requirements specified above; 9) those who have partici-
pated in a clinical trial of an investigational drug within
the past 1 month; 10) history of lithium toxicity, not due
to mismanagement or overdose that required treatment.
Dosing
Lithium carbonate will be started at 300 mg at bedtime.
After 3 days, participants will be advised to increase the
dosage to 600 mg, and then the dose will be titrated as
clinically appropriate to maximum well-tolerated doses
based on blood levels. Subsequent adjustments will be
made at the discretion of the treating clinician, consider-
ing patient tolerability, response, and other medications
included in treatment as part of TAU. Clinicians may in-
crease the dose as clinically indicated and tolerated, not
to exceed serum levels of 1.2 mEq/L. Clinicians will be
discouraged from any dose increases that are expected
to result in unacceptable tolerability. Similarly, at any
time during study participation, if the 600 mg/day dose
is not tolerated, the dose may be decreased to a mini-
mum of 300 mg/day. Patients who cannot tolerate
300 mg/day of lithium will continue to receive TAU and
otherwise adhere to study protocol and procedures for
the duration of the trial. Treating psychiatrists will be
asked to manage the patients as they would any other
patient, adjusting medications as needed in response to
clinical exacerbations or side effects.
TAU
The foundation of TAU is to maintain treatment with at
least one FDA approved mood stabilizer and to follow the
recommendations summarized in the evidence-based
stages of Texas Implementation of Medication Algorithm
(TIMA) revised guidelines [43]. For all patients, TAU will
require the presence of at least one FDA-approved mood
stabilizer and antidepressant medications will only be pre-
scribed in combination with a mood stabilizing drug, as
described in the TIMA guidelines.
Medication management
All participants will receive usual treatments for bipolar dis-
order [90] provided by either the investigator, clinical
psychiatrists or psychiatry residents trained, certified, and
supervised in optimal treatment practices for bipolar dis-
order within investigator-directed clinics. Where medica-
tion checks are being provided by non-investigator
clinicians, the role of the investigator will be to monitor
and/or influence/advise treatment taking place in their
clinic.
Medication checks will take place every 2–4 weeks
during the Open Stabilization Phase and/or as clinically
indicated and weekly during the 1-month Observation
phase. Medication checks during the Relapse Prevention
Phase will take place every 2 months as clinically indi-
cated. The frequency of medication checks will be ad-
justed as clinically appropriate at any time during the
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study based on the current clinical status of subjects in
the study.
The CGI-S-BP for Overall Bipolar Illness, for Depression,
and for Mania will be completed by the treating psychiatrist
at every medication check. For subjects who are believed to
be relapsing, the treating psychiatrist will complete a DSM-
IV mood episode checklist for major depressive episodes,
manic episodes, and mixed episodes.
Physical and laboratory monitoring
During the baseline period, vital signs and weight will be
recorded. In addition, an EKG will be required for par-
ticipants over the age of 40 as clinically indicated. The
EKG requirement will be waived if an EKG had been ob-
tained within 3 months of the baseline visit and a report is
available. Laboratory assessments of BUN, creatinine, elec-
trolytes, TSH and a urine pregnancy test (if applicable)
will be obtained at baseline and will be repeated based on
APA guidelines for recommended lithium monitoring
(see Tables 1 and 2). Drug screens will not be routinely
administered; however, administration of drug screening
as part of ongoing treatment is at the discretion of the
treating physician at any time, after consultation with the
participant.
Assessments
Demographics: Age, sex, years of education, race, marital
status, income, smoking status, employment history, and
other demographic information will be recorded at base-
line. The course followed by these patients after the
study ends may offer rewarding opportunities to assess
genetic correlates of long-term outcome in a sample
with well-documented treatment responses. For this rea-
son, we will also ask subjects to provide consent for
future contact, as well as the names, addresses and tele-
phone numbers of two individuals likely to know the
subject’s future whereabouts, and the subject’s driver’s
license number.
Diagnosis
The Diagnostic Interview for Genetic Studies (DIGS) will
be used to make DSM-IV diagnoses and to collect detailed
historical clinical information. This instrument was
developed to obtain very fine grain information about the
symptoms and course of bipolar disorder. It has also been
modified to collect retrospective medication response in-
formation. It has been validated by numerous studies and
used for our collection of 4,500 subjects.
Clinical course
Data will be collected on course of illness prior to
randomization, including age of onset for bipolar disorder,
number of prior episodes, past treatment response,
childhood abuse (emotional, physical, sexual), medical con-
ditions, psychoactive substance use, family history, prior
lithium treatment and prior suicide attempt history, includ-
ing lethality. Specifically, a history of episodes in the previ-
ous 2 years will be taken using a life chart method. This
will be used as a covariate to correct for natural course in
the statistical analysis.
Symptom severity
1. Clinical Global Impressions of Severity Scale-Bipolar
Version (CGI-BP) [44]. The CGI-BP is a modified
version of the original CGI designed specifically for
use in assessing global illness severity and/or change
in patients with bipolar disorder; it assesses overall
bipolar illness, depression, and mania. While the
original CGI has been criticized for lack of reliability,
the CGI-BP has been shown to have excellent
inter-rater reliability. Not surprisingly, placebo re-
sponse rates have been shown to be lower with the
Table 1 Lab monitoring schedule
Baseline Stabilization Oa Mb
Test Baseline 2 weeks 12 weeks 16 weeks Every 6 months during 24 months of additional follow-up
Vitals/Weight X X X
EKGc X if age > 40
BUN X X X
Creatinine X X X
Pregnancy X
TSH X X X
CBC X
Electrolytes X X X
Lithium X X X X X
Genetics Samples X
aObservation phase
bMaintenance phase
cIf clinically indicated, as determined by the study physician
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CGI-BP, compared to the HAM-D or MADRS in bi-
polar disorder. In contrast to symptom-severity
scales, the CGI-BP is an integrated measure of
illness severity that permits the incorporation of an
assessment of function at work, social, family
settings, etc. In contrast to the MADRS and HAM-D,
it is not encumbered by the inability to distinguish
improved somatic function (appetite and sleep)
from medication-induced adverse events, which is
important when studying medications that cause
weight gain or somnolence.
2. Montgomery Asberg Depression Rating Scale
(MADRS) [45]. A 10-item clinician-rated measure of
depression will be used to examine the extent of
each patient’s current depressive symptoms.
3. Young Mania Rating Scale (YMRS) [46]. An 11-
item, clinician-rated measure that queries symptoms
of mania.
4. Clinician Administered Rating Scale for Mania
(CARS-M) [47]. The CARS-M is a reliable and valid
15-item, clinician-rated measure of mania The
CARS-M incorporates a number of methodological
improvements in comparison to more frequently
utilized mania rating scales, such as the YMRS. For
example, the CARS-M separately assesses the
presence of psychotic symptoms (e.g., delusions and
hallucinations). Given the overlap in symptoms
assessed on the YMRS and CARS-M, an integrated
version will be developed and utilized for the
current study, minimizing patient burden, yet
allowing full-scale scores to be derived for each
measure.
5. Quick Inventory of Depressive Symptomatology
Self-Report (QIDS-SR16) [48]. A 16-item self-report
measure of depressive symptoms.
Neurocognitive assessment
Neurocognition will be assessed for several reasons.
Bipolar subjects with cognitive deficits may comprise
a distinct group with a different disease mechanism.
If this is the case, neurocognitive measures may cor-
relate with response and serve as an endophenotype
for response [49], substantially increasing the power
to detect genes. Another reason has to do with side
effects. Not only are such deficits part of the core
bipolar phenotype, they may also be induced by
medications. Cognitive slowing is a not uncommon
side effect for many mood stabilizers. Testing may
enable us to determine if these are markers for re-
sponse, side effects or relapse, and if they are associ-
ated with specific genes.
Based on a review of previous published data on cog-
nitive dysfunction in bipolar disorder and the heritabil-
ities of several neurocognitive measures, our overall
assessment strategy will focus on a brief measurement of
three domains: attention, verbal learning, and executive
function. The proposed neurocognitive battery can be
administered in approximately 25 min and will consist
of 5 measures (see Spreen & Strauss, 1998 for test
citations):
Table 2 Assessment schedule (time in weeks)
B Stabilization O Maintenance
-1 0 4 8 12 14 16 Q 2 wks × 8 wks then monthly visits Cross over to Valproic Acid for
mood episode on lithium
CGI-S-BP by doctor X X X X X X X X X
Mood episode checklist X X X X X X X X X
Consent X
MINI- PLUS X
Demographics/course of illness X
HAM-A X X X X
MADRS X X X X X X
QIDS-SR 16 X X X X X X X X X
YMRS/CARS – M X X X X X
Side Effects Survey X X X X X X X X X
Q-LES-Q X X X X
IRS X X X X
MSSI X X X X X X
Serious Adverse Event Form X X X X X X X X
O observation phase, B baseline, ET Early Termination, Mini-PLUS Extended Mini-International Neuropsychiatric Interview, MADRS Montgomery Asberg Depression
Rating Scale, QIDS-SR 16 Quick Inventory of Depressive Symptomatology Self-Report, YMRS Young Mania Rating Scale, CARS-M: Clinician Administered Rating Scale
for Mania, HAM-A Hamilton Anxiety Rating Scale, CGI-BP Clinical Global Impressions of Severity - Bipolar Version, Q-LES-Q quality of life, enjoyment, and satisfaction
questionnaire, IRS impulsivity rating scale, MSSI The Modified Scale of Suicidal Ideation
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1. Wide Range Achievement Test (3 minutes) - Third
Edition, Reading (WRAT-3). The WRAT-3 Reading
subtest assesses single-word reading skill.
2. WAIS-III, Digit Symbol Subtest (3 minutes). The
WAIS-III Digit Symbol subtest task measures both
visual scanning and graphomotor speed.
3. The Stroop Color Word Test (SCWT) (4 minutes)
(Golden version). The SCWT is a commonly used
executive functioning task measuring inhibitory or
cognitive control.
4. Controlled Oral Word Association Test (5 minutes).
The COWAT measures the ability to verbally
produce words and is considered by most
neuropsychologists to be a task of executive
function.
5. California Verbal Learning Test (CVLT)
(15 minutes). The CVLT measures the processes
and strategies involved in learning and retaining
verbal material. Recent data support a familial
component for impaired performance on the CVLT
in bipolar disease patients and their unaffected
co-twins [50]. COMT genotype has been associated
with performance on the CVLT in patients with
bipolar I disorder [51].
Quality of life and functioning
Quality of Life, Enjoyment, and Satisfaction Question-
naire (Q-LES-Q) [52]. Assesses subjective quality of life
(i.e., physical health, subjective feelings, leisure activities
and social relationships).
Impulsivity and suicidal behavior
1. Impulsivity Rating Scale (IRS). [53] The IRS is a 7-
item clinician-rated assessment of impulsivity. It
uses a 0 to 3 scale to rate irritability, impatience,
decision-making, distractibility, aggressiveness,
response control, and delayed gratification.
2. The Modified Scale for Suicidal Ideation (MSSI).
[54] The MSSI is an 18-item clinician-administered
scale that monitors intensity of ideation, courage
and competence to attempt suicide, and talk and
writing about death over the past year. The first 4
items have been designated as screening items to
identify those individuals whose suicide ideation is
severe enough to warrant the administration of the
entire scale. Each item is rated on a 0-3 point scale,
and the ratings are summed to yield a total score
ranging from 0 to 54.
Side effects
Frequency and Intensity of Side Effects Ratings. A 3-
item self-rated measure of medication side effects.
Serious adverse events (SAEs)
SAEs will be systematically recorded to assess any life-
threatening events or hospitalizations. An SAE is defined
as any adverse drug experience occurring at any dose
that results in any of the following outcomes:
 life-threatening event, including suicide attempts
 death
 hospitalization/prolongation of hospitalization
 congenital anomaly
 persistent or significant disability/incapacity
 required intervention to prevent permanent
impairment/damage
Definitions of lithium relapse and spectrum of efficacy
There is emerging consensus that compounds that pos-
sess relapse and recurrence prevention efficacy in bipolar
disorder stabilize mood by different mechanisms. Com-
pounds that stabilize mood from both above and below
baseline are viewed as having bimodal efficacy, e.g., they
are able to delay or prevent both depressive and manic
episodes. Those that stabilize mood by delaying or pre-
venting episodes from below baseline are described as
having the ability to delay or prevent depressive episodes
without causing treatment-emergent mania, whereas
those that stabilize mood from above baseline are believed
to delay or prevent manic episodes without causing
treatment-emergent depression. To identify pharmacoge-
netic predictors of spectrum of efficacy by mood state, the
following definitions of relapse will be used:
Manic Relapse will be defined as patients who meet
DSM-IV criteria for a manic episode but not a major
depressive episode.
Depressive Relapse will be defined as patients who
meet DSM-IV criteria for a major depressive episode
but not mania or hypomania. In addition, the duration
of the episode must be 4 weeks instead of 2.
Mixed Relapse will be defined as patients who meet the
DSM-IV criteria for a major depressive episode and a
manic episode.
Clinician’s Judgment. In addition to the DSM-IV
defined relapse criteria, a patient may be deemed a
relapse if, in the judgment of the treating physician, the
current regimen is not working and it is clinically
necessary to make a change in medications.
Criteria for discontinuation
Participants may be discontinued from the study at any
time at investigator discretion. Specific reasons for dis-
continuing are 1) withdrawal of informed consent; 2)
pregnancy; 3) clinically significant or serious adverse
event not consistent with continuation in study, as
determined by investigator or participant; and 4)
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suspension or termination of the study, study site, or at
investigator discretion.
Valproate crossover
Participants who are unable to tolerate lithium or fail to
achieve relapse prevention on lithium will be crossed over
to treatment with valproic acid in an identically designed
second phase, including a 3-month stabilization phase, 1-
month observation phase, and a relapse prevention phase
of up to 24 months. Measurement of valproate response
in a subset of subjects will make it possible to test whether
SNPs associated with lithium response are also associated
with valproate response.
IPSC studies of lithium response
We propose to create cell-based human models for lith-
ium response in bipolar disorder by reprogramming skin
fibroblasts from lithium-responsive and non-responsive
bipolar disorder patients into human induced pluripo-
tent stem cells (hiPSCs) (Fig. 1). By differentiating these
disorder-specific hiPSCs into neurons, we hope to not
only identify specific neuronal defects associated with bi-
polar disorder neurons in vitro but also elucidate the
molecular and cellular mechanisms of lithium respon-
siveness and non-responsiveness in bipolar disorder.
Gene expression studies will be used to identify high-priority
candidate genes and to study gene networks
In particular, gene expression will be studied using
RNA-seq in cells from responders and non-responders
treated with and without lithium, as illustrated in Fig. 2.
Genes whose expression is significantly changed in
response to lithium in responders but not non-
responders will comprise a set of high-priority candidate
genes for further study. This set of genes will then be
used for detailed genotyping and sequencing studies of the
DNAs from the prospective study participants. By using
biology to develop a reduced set of a priori selected candi-
date genes, we can substantially reduce the number of
statistical tests and preserve the statistical power of our
sample. This strategy assumes that some of the same
genes displaying differential change in expression also
contain the variants affecting lithium response. Candidate
genes may also be selected from other sources such as
published literature or results from the ConLiGen consor-
tium, animal or cellular studies.
The gene expression data will also be used to develop
gene expression networks that can then be compared
between the four conditions. It is likely that, more than
specific genes, it is changes in the functional modules or
groups of genes that are most robustly changed in re-
sponse to lithium. Such a network-based approach may
also be more informative regarding the biology that is al-
tered by lithium and different in responders.
Genotyping and genetic data
Genotyping will be completed using PsychChip, which
was developed on an Illumina platform for the Psychi-
atric Genomics Consortium (PGC). This chip includes
the 50,000 most significant SNPs from several psychi-
atric disorders, as well as 250 K SNPs exome and frame-
work GWAS content. We will use PLINK (http://
pngu.mgh.harvard.edu/purcell/plink/) to evaluate and
clean the genetic data received from TGen for 1)
Fig. 1 iPSC-derived neurons as a cellular model of bipolar disorder and lithium response. Fibroblasts are grown from skin biopsies taken from
participating subjects. These cells are treated with a combination of four transcription factors that reprogram the cells to stem cells. These iPSCs
are then treated with a series of growth factors to differentiate them into a variety of neuronal types. In this way, neurons from patients can be
compared to controls or lithium responders to non-responders
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genotypic completeness, 2) average SNP heterozygosity,
and 3) average genotyping quality score. For each SNP we
will review 1) genotypic completeness, 2) average SNP het-
erozygosity, 3) average genotypic quality score, 4) minor al-
lele frequency (MAF), and 5) p-values for tests of deviation
from Hardy-Weinberg equilibrium. After generating a
filtered dataset, we will examine Q-Q plots of associ-
ation statistics with case-control status defined by
good versus poor responders in order to look for
systematic deviations from expectation that may fur-
ther reflect artefacts in the data. Through these pro-
cedures, we will generate a final, cleaned dataset for
the downstream analyses. Notable findings will all be
reviewed in further detail as a final quality control
check to confirm that they are not due to artefacts
of low MAF, low genotyping completeness, batch or
laboratory effects, or population stratification. In
addition, we will visually examine the actual intensity
plots of the individual best SNPs to confirm the
quality of the genotype calls and ensure there is no
evidence of systematic error that might lead to
spurious results.
Statistics
For the analysis of the Prospective Study, we will exam-
ine the outcome for lithium response as a time to event,
where the event is defined as clinical relapse as defined
above. For this we will use Cox Proportional Hazards
models of the form:
log h tð Þ ¼ α tð Þ þ β1X1 þ … þ βkXk
where h(t) is the hazard of relapse at time (t) and the
time axis is defined as the time from stabilization on
drug to either clinical relapse, censoring due to loss to
follow-up or discontinuation of study medication, or the
end of the follow-up period. This model is semi-
parametric in that the baseline hazard of relapse can take
any form, but the covariates enter the model linearly and
are assumed to have constant relative hazard over the en-
tire time period. This assumption of constant relative haz-
ard over time can be evaluated (and remedied if needed) by
including in the model interactions terms between the co-
variate of interest and time. Building on this framework, we
will test in separate models whether the SNPs identified in
the ConLIGen Retrospective Study are significantly associ-
ated with the relative hazard of clinical relapse. We will in-
clude in the models covariates for age, sex, clinical site, and
up to 10 quantitative indices of ancestry (if preliminary ana-
lyses of the genetic data suggest evidence of population
stratification in the sample) to control for the potential con-
founding effects on these associations. We will also be able
to include a covariate for an indicator variable capturing
whether the patient entered the prospective study already
Fig. 2 Using cellular phenotypes to identify likely lithium-responsive genes. To reduce the number of comparisons and preserve statistical
power, iPSC-derived neurons will be used to identify a smaller number of genes likely to be involved in lithium’s action. iPSC-derived neurons
from lithium responders and non-responders will be treated both with and without lithium. RNAseq will be conducted and genes sought
whose expression changes in responders but not non-responders. These genes will comprise a limited number of a priori hypotheses for
initial testing
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on lithium as allowed by the protocol in order to control
for this as well as to test whether associations differ for
these versus other patients.
We will also examine repeated quantitative measures
of depressive or manic symptoms taken at regular inter-
vals over the period of follow-up. This will address the
number of symptoms subjects continued to suffer even
when they were considered in remission. For the re-
peated measures analyses, we will use longitudinal data
methods to associate SNPs with differences in symptom
measures over time. In particular, we will use linear re-
gression models with general estimating equations
(GEE) to account for the correlation engendered by re-
peated measures on the same participants. We will ex-
plore the repeated measures data to diagnose the nature
of this correlation and then treat it as a nuisance variable
in the model. We will then test whether the SNPs identi-
fied in the Retrospective Study or other retrospective
datasets (ConLiGen) are significantly associated with dif-
ferences in mean scores on the measures of depressive
or manic symptoms, controlling for time of assessment,
age, sex, clinical site, and the same quantitative indices
of ancestry as the in the Cox model if deemed necessary.
We will further explore for possible interactions between
the SNP and time to test whether the effect of the SNP
on depressive or manic symptoms changes over time.
To determine whether the effects of SNPs found to be
associated with response in these analyses are specific to
lithium treatment, we will use two strategies. First, in
the time to event and repeated measures analyses de-
scribed above, we will examine whether the inclusion of
a covariate describing prior disease episode frequency af-
fects the estimated association between SNPs and clin-
ical relapse and/or symptom differences. If the estimated
association is mitigated, this will suggest that the SNPs
are associated with the natural course of disease in gen-
eral. If, however, the estimated association persists, this
will suggest that the association is specific to lithium re-
sponsiveness. To further confirm this possibility, we will
examine the data from the Depakote arm of the Pro-
spective Study. We will test whether the identified SNPs
predict clinical relapse or symptom differences among
patients who are crossed over to Depakote. If they are
not associated, this will suggest the variants are asso-
ciated specifically with lithium responsiveness.
Power
We calculated the power for the survival analysis of the
Prospective Study following the methods of Lakatos [55]
based on a proportional hazards model and assuming a
nominal significance alpha of 0.05. We further assumed
a dominant model to simplify the calculations, but note
that this model typically provides a conservative estimate
of power compared to a log additive model, which is
what we plan to assume in the analyses. Finally, we as-
sumed 2 years of follow-up with a relapse rate of 50 %
among participants with the wild type genotype. Figure 3
below shows the power of our sample to identify a sig-
nificant association under these conditions for an esti-
mated sample of 700 patients in the Prospective Study
for various hazard ratios and minor allele frequencies.
As described above, we plan a two-stage analysis in which
a small number of a priori hypotheses will be tested in stage
1 so as to preserve power. SNPs to be tested in this stage
will be selected from our collaborating retrospective lithium
study, ConLiGen, significant SNPs from our retrospective
sample, SNPs reported in the literature and those selected
from expression studies of iPSC-derived neurons. In a sec-
ond stage of analysis, a full GWAS will be conducted as an
exploratory analysis to discover novel variants that may be
replicated in other samples.
Ethics
This international study will be conducted in nine clin-
ical centers in the US, one in Canada, and one in
Norway. The study sponsors are the National Institutes
of Mental Health and General Medical Sciences in the
US (MH92758), The Western Norway Regional Health
Authority and the Canadian Institutes of Health Re-
search (#64410). The study protocol has been approved
by both the local IRB’s at all US sites and in Canada, as
well as the Ethics Committee and Health Authorities in
Norway. The investigator is responsible for ensuring that
Fig. 3 Power of survival analysis as a function of hazard ratio and
allele frequency for 700 subjects. Power analyses indicate that a
sample of 700 subjects will have about 80 % power to detect a
hazard ratio of 1.4
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no patient is subject to any study-related examination or
activity before that patient has given written informed
consent after the receipt of detailed information. The in-
vestigator will inform the patient of the aims, methods,
anticipated benefits and potential hazards of the study,
including any discomfort it may entail. This information
will be summarized in integrated patient information
and consent sheets. All sites participating in the collec-
tion of fibroblasts have obtained an additional IRB ap-
proval for the iPSC studies and all additional informed
consents regarding this procedure have been obtained.”
The study has been registered on the EudraCT database
(EudraCT number 2010-023740-32) and at Clinical-
Trials.gov (NCT01272531). The trial will be conducted
in accordance with the latest version of the Declaration
of Helsinki and the International Conference on
Harmonization (ICH) - Good Clinical Practice (GCP)
guidelines for clinical trials. The ethics committees are
as follows:
Regional committees for medical and health research
ethics: REC South East, University of Bergen
The University Hospitals Institutional Review Board
(IRB), University Hospitals, Cleveland, OH
Capital Health Research Ethics Board, Center for
Human Research, Dalhousie University
Human Subjects Office/Institutional Research Board,
University of Iowa
Office of Research Compliance – Indiana University
Office of Human Subjects Research Institutional
Review Boards, Johns Hopkins University
Mayo Clinic Institutional Research Board
Human Research Protection Program (HRPP),
University of Michigan
University of Pennsylvania, Institutional Research Board
BSD IRB Committee C, University of Chicago
Human Research Protections Program, University of
California, San Diego
Discussion
Based upon the well-established clinical efficacy of lith-
ium in the treatment of bipolar disorder, we present here
the study protocol of a large, multicenter prospective
study designed to identify genetic predictors of good
lithium response. The study is an 11-site open non-
randomized trial of 700 Bipolar I patients treated with
lithium monotherapy and followed for up 2 years. The
long-range goal of the study is to better understand
lithium’s mechanism of action and to develop a possible
DNA test panel that will aid physicians in medication
selection.
During the study development, the following factors
were considered:
1. Prospective vs retrospective. Almost all previous
studies of lithium response have been done using
standardized chart review and retrospective response
data, which has the advantage of surveying the
subject’s entire lifetime experience on lithium.
However, it suffers the serious disadvantages of poor
recall, state-related recall, lack of monotherapy
(in general), qualitative instead of quantitative data
and lack of observer ratings. For these reasons, we
chose a prospective design. Though the much
greater effort and expense will only allow for smaller
sample sizes, we deemed the accuracy and superiority
of the data to be the more important factors. This
sample may serve as a “gold standard” sample for
future studies, especially for replication of results.
2. How many mood stabilizers to study? We
considered a design where subjects would be
randomized between lithium and two other mood
stabilizers such as lamotrigine or valproate. Though
this design would have given us invaluable
comparative information, we chose instead to have a
larger sample size and better statistical power for
one drug, lithium. The crossover of lithium failures
to valproate provides some opportunity for
comparison.
3. How to distinguish gene effects from natural course?
If a genetic variant shows association to response,
how do we know that this reflects the subject’s
response to lithium vs. simply the natural course of
the illness? Specifically, how do we know that a SNP
is associated to lithium response or simply rapid
cycling and is unrelated to drug? The scientifically
ideal design would be to include a placebo arm as a
control for natural course. However, given the
severity of bipolar disorder, we deemed it neither
ethical nor feasible to include such an arm. Instead,
we have employed a detailed collection of
information about lifetime cycling to covary for this
effect. Of note, in the Perlis et al. study of lithium
response in the STEP-BD sample, a similar inclusion
of rapid cycling as a covariate had no effect on the
results [42].
4. Monotherapy. Though perhaps a therapeutic ideal,
monotherapy using any drug is not usually achieved
in the management of bipolar disorder. However, if
we allowed multiple drugs, then we would remain
unclear as to which drug was driving the response
and to which drug a genetic variant is associated.
For these reasons, we chose to require monotherapy,
though it excludes partial responders and the
generalizability.
5. Acute vs prophylactic response. A shorter and faster
study might have focused on the acute response to
lithium in treatment of depression, mania or mixed
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states. However, the most widely used application
for lithium is prophylaxis, and by studying relapse
prevention we focus on the greatest clinical utility.
Most patients also enter the study on other
medications and the acute stabilization period is
confounded by these other medications and the
changes in medications during this period
6. Duration of follow up. Twenty-four months of
follow up was selected because the STEP-BD study
showed that, at 2 years, about 50 % of treated bipolar
I patients had relapsed. Two years was therefore
selected to maximize power.
In summary, only a limited investigation has been
made of this area. Generally only a few genes have been
tested and samples are largely retrospective. STEP-BD is
the only truly prospective study, yet only about 200 sub-
jects achieved monotherapy; other results are con-
founded by concomitant meds. There is a need for
larger, better characterized samples and a more system-
atic approach to this area.
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